mutant + WT CFTR Cl channel potentiator

oral 300 mg BID , Ph. II in COPD and CF

from 1M cmpd cell-based HTS + opt.

J. Med. Chem., May 24, 2021

Millenium/Takeda, Cambridge, MA

Icenticaftor

The Novartis mutant and WT CFTR potentiator, icenticaftor (QBW251), is an oral Ph. II clinical candidate for chronic obstructive pulmonary disease (COPD), which is anticipated to become the 3rd leading cause…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: